Mammary Cell News 8.28 July 21, 2016 | |
| |
TOP STORYUncovering a New Principle in Chemotherapy Resistance in Breast Cancer A laboratory study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes. [Press release from the National Cancer Institute discussing online prepublication in Nature] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHSMARCA4 knockdown in human mammary epithelial MCF-10A cells resulted in 176 up-regulated genes, including many related to lipid and calcium metabolism, and 1292 down-regulated genes, some of which encode extracellular matrix components that can exert mechanical forces and affect nuclear structure. [Genome Res] Abstract MicroRNA-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway Investigators report that hsa-miR-206 suppresses breast tumor stemness and metastasis by inhibiting both self-renewal and invasion. [Clin Cancer Res] Abstract The authors’ previous study showed that 4-hydroxyestradiol (4-OHE2)-induced production of reactive oxygen species contributed to neoplastic transformation of human breast epithelial (MCF-10A) cells. In this study, 4-OHE2, but not estrogen, increased the expression of heme oxygenase-1, a sensor and regulator of oxidative stress, in MCF-10A cells. [Oncotarget] Full Article Neoadjuvant chemotherapy (NCT) is one of the main treatment strategies for patients with locally advanced breast cancer. Scientists focused on the predictive and prognostic value of Ki-67 in triple-negative breast cancer patients who received NCT. [Sci Rep] Full Article The authors report that a TRIM28-TWIST1-epithelial-to-mesenchymal transition (EMT) axis exists in breast cancer cells and TRIM28 promotes breast cancer metastasis by stabilizing TWIST1 and subsequently enhancing EMT. [Sci Rep] Full Article Ferroptosis Is Induced following Siramesine and Lapatinib Treatment of Breast Cancer Cells Investigators demonstrated that lysosome disrupting agent, siramesine and a tyrosine kinase inhibitor, lapatinib synergistically induced cell death and reactive oxygen species in MDA MB 231, MCF-7, ZR-75 and SKBr3 breast cancer cells over a 24 hour time course. [Cell Death Dis] Full Article Tamoxifen Metabolite Endoxifen Interferes with the Polyamine Pathway in Breast Cancer Endoxifen is recognized as the active metabolite of tamoxifen in humans. Researchers studied endoxifen effects on estrogen receptor α-positive MCF-7 breast cancer cells. [Amino Acids] Abstract Scientists studied the migratory and invasive features and the expression of proteins related to these processes on HB4a-Ras cells after three successive cycles of photodynamic therapy using different photosensitizing drug: 5-aminolevulinic acid, Verteporfin, m-tetrahydroxyphenylchlorin and Merocyanine 540. [J Cell Biochem] Abstract Scientists used the dimethylbenz[a]-anthracene-induced model of luminal mammary cancer in Sprague Dawley rats to elucidate which microRNAs are linked to progression in this type of cancer and, subsequently, to study how calorie restriction affects such microRNAs. [PLoS One] Full Article CLINICAL RESEARCHThe authors describe the outcome following first-line paclitaxel with or without bevacizumab in the French Epidemiological Strategy and Medical Economics database of metastatic breast cancer patients, established in 2014 by Unicancer. Primary and secondary endpoints were overall survival and progression-free survival, respectively. [Ann Oncol] Abstract | |
| |
REVIEWSRecent studies have indicated that particular miRNA signatures are correlated with tumor aggressiveness, response to drug therapy and patient outcome in breast cancer. On the other hand, in routine clinical practice, the treatment regimens for breast cancer are determined based on the intrinsic subtype of the primary tumor. [J Hum Genet] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field.
| |
INDUSTRY NEWSAmgen and Allergan plc announced results from a Phase III study evaluating efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive early breast cancer. [Amgen] Press Release Synaffix BV announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. [Synaffix BV] Press Release Invitae Corporation announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic testing designed for breast cancer patients whose providers need a fast turnaround time to guide treatment and management. [Invitae Corporation] Press Release | |
From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
| |
POLICY NEWSNIH Expands Investment in HIV Cure Research The National Institutes of Health has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. [National Institutes of Health] Editorial Drugs Watchdog Thwarting UK Progress in Stem Cell Therapy, Report Says Britain’s hopes of leading the world in revolutionary therapies that regenerate damaged body parts are under threat because the NHS drugs watchdog cannot properly evaluate them, a report says. [The Guardian] Editorial | Report Science’s Status Shifts in New Brexit Government Three weeks after UK voters chose to leave the European Union, the country has a new prime minister, Theresa May — and a revamped administration that is poised to change science’s place in government. [Nature News] Editorial Science Under Siege: How Venezuela’s Economic Crisis Is Affecting Researchers The political and economic crisis in Venezuela continues to worsen. As the price of oil — the country’s major export — has fallen, Venezuela has struggled to pay for imported goods while maintaining socialist economic policies put in place by former president Hugo Chávez. [Nature News] Editorial Research Charities Help Marry Two Major South African HIV/Tuberculosis Institutes As the International AIDS Conference kicked off in Durban, South Africa, two of the nation’s most prominent biomedical research institutions announced that they will marry and combine resources to attack the raging coepidemic of tuberculosis and HIV in the region. [ScienceInsider] Editorial A Week of Political Bloodletting, but U.K. Science Minister Keeps His Job For researchers worried about the future of science in the United Kingdom, the news was something to hold onto. Late on Friday, Jo Johnson announced he will remain as science minister, despite a massive shakeup of the government cabinet. [ScienceInsider] Editorial Turkey Purges Universities after Failed Coup More than a thousand Turkish university staff have been ordered to resign their faculty leadership positions — and others expect to be sacked — in the aftermath of the country’s failed coup. As president Recep Tayyip Erdoğan continues to clamp down on political opposition, the Turkish Council of Higher Education has called for all 1,577 of the country’s university deans — the staff that head up each institution’s various academic faculties — to leave their posts. [Nature News] Editorial Dutch Agency Launches First Grants Program Dedicated to Replication The Netherlands has launched what researchers say is the world’s first national fund dedicated to replication studies: a pot of €3 million (US$3.3 million) over the next 3 years for Dutch scientists to test whether they can reproduce important research results in social and medical sciences. [Nature News] Editorial Younger Researchers Win NIH Grants at Rates Similar to Their Elders Younger biomedical researchers—those between 35 and 39—are about as likely to win funding from the National Institutes of Health (NIH) as their elders, according to a study published earlier this month in Cell Stem Cell. This finding seems to upend the widespread impression that older scientists have higher success rates than their juniors in the competition for grants. [Science Careers] Editorial Bill to Reform U.S. Skilled Worker Visa Programs Is Effort to ‘Build Momentum Lawmakers don’t usually acknowledge that the bills they introduce in Congress have little chance of passage in the near future, but that’s what Representative Bill Pascrell, Jr., (D-NJ) did in an 18 July phone press conference to discuss the H-1B and L-1 Visa Reform Act of 2016, which he introduced in the House of Representatives on 8 July. Still, “we’re trying to build momentum” and raise awareness of the need to reform these high-skill guest worker visa programs, he said. [Science Careers] Editorial
| |
EVENTSNEW 28th European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) Symposium Visit our events page to see a complete list of events in the mammary cell community.
| |
JOB OPPORTUNITIESNEW Scientific Director – Global Medical Affairs (Celgene Corporation) NEW Research Assistant – Role of Platelets in Breast Cancer Metastases (Jagiellonian University) NEW Postdoctoral Position – Metastatic Reactivaction of Cancer (MD Anderson Cancer Center) Scientific Director – Oncology (Merck) Postdoctoral Fellow – Various Projects (National University of Singapore) Postdoctoral Fellow – Breast Cancer Monitoring through Digital Imaging (University Rovira i Virgili) Postdoctoral Researcher – Basic & Translational Breast Cancer Research (Northwestern University) Postdoctoral Associate – Premalignant Progression to Invasive Breast Cancer (Tulane Medical School) Postdoctoral Fellow – Molecular Genetics of Breast Cancer (German Cancer Research Centre) Postdoctoral Fellowship – Cancer Research (German Cancer Research Center) Postdoctoral Fellow – Proteogenomic Bioinformatics of Breast Cancer (Lund University) PhD Fellow – Small X-Ray Angle for Breast Cancer Diagnosis (CEA Tech) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.28 | Jul 21 2016